Device Trial Radar · NCT06634719
Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Feb 1, 2025
Primary completion
Apr 22, 2026
Study completion May 22, 2026
Sponsor
- Lead sponsor
- Rejoni Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.
Conditions
- Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel SystemDevice
The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: Within 7 days post-treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Applied Research Center of Arkansas
Little Rock, Arkansas
Rubino OB/GYN (Axia Women's Health)
West Orange, New Jersey
Seven Hills Clinical Research Group, LLC
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.